CyberHeart Takes Non-invasive Approach To AF Ablation
Executive Summary
CyberHeart Inc. is developing a non-invasive approach to cardiac dysrhythmia ablation by adapting technology from CyberKnife, the radiosurgery system for cancer treatment. Current clinical trials are examining the use of CyberHeart not only for atrial fibrillation (AF) treatment, but also for ventricular tachycardia, for which a US pivotal trial is scheduled for early 2017.
You may also be interested in...
WashU Researchers Plan Major Trial Of Noninvasive Radiation Ablation For Ventricular Tachycardia
Physicians developing a promising technique for noninvasive cardiac radioablation for ventricular tachycardia are working with US FDA to develop a large multicenter trial of their technique following the success of a five-patient case-series and an 18-patient prospective study.
COVID-19 Lessons: Experts Predict Shift Toward Intermittent Hemodialysis In ICUs
The pandemic may accelerate a move toward versatile, single-solution renal replacement therapy in intensive care.